Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

• Status: Completed
• Trial end date: 2022-01-10
• Target enrollment: 0
• Participant gender: All

Summary

Our trial goal is to determine the efficacy and safety of sitagliptin in comparison with empagliflozin in type 2 diabetic Egyptian patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sadat City University
• Collaborator: Beni-Suef University
• Treatments: Dipeptidyl-Peptidase IV Inhibitors; Empagliflozin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors

Criteria

Inclusion Criteria:

• Type 2 male/female diabetic patients

• Age 20-70 years

• A1C less than 10.5%

Exclusion Criteria:

• Type 1 diabetes; HbA1c > 10.5%

• Pregnancy

• Chronic liver disease

• Elevated (more than twofold the upper limit of normal) ALT, AST and CPK.

• High bilirubin

• Albumin < 3.5 g/dl

• INR >1-2 Diabetic ketoacidosis

• Urinary tract infection (UTI)

• Pancreatitis < 6 months prior to enrolment

• Renal impairment (creatinine clearance ≤50 ml/min)

• Treatment with anti-obesity drugs or glucagon-like peptide-1 receptor agonists (GLP-1RAs) 3 months prior to enrolment

• Non-compliance with follow-up visits.